ストックスクリーナーアプリを入手
52.66
1.99%
-1.07
Moonlake Immunotherapeutics (MLTX) 最新ニュース
MoonLake Immunotherapeutics Shows Early Signs of Technical StrengthJuly 2025 Drop Watch & AI Enhanced Market Trend Forecasts - beatles.ru
Does MoonLake Immunotherapeutics have pricing powerWall Street Watch & High Accuracy Trade Signal Alerts - thegnnews.com
I'm Over the Moon About This Promising Biotech - TheStreet Pro
Ranking MoonLake Immunotherapeutics among high performing stocks via toolsPrice Action & AI Driven Stock Movement Reports - Newser
Real time social sentiment graph for MoonLake ImmunotherapeuticsInsider Buying & Stock Portfolio Risk Control - Newser
MoonLake Immunotherapeutics: A High-Conviction Speculative Play on Sonelokimab's Transformative Potential - AInvest
MoonLake Immunotherapeutics (MLTX): A Bull Case Theory - MSN
What data driven models say about MoonLake Immunotherapeutics’s futureQuarterly Risk Review & Daily Risk Controlled Trade Plans - Newser
When is the best time to exit MoonLake ImmunotherapeuticsJuly 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
MoonLake Immunotherapeutics stock trend outlook and recovery path2025 Volatility Report & Safe Capital Growth Plans - Newser
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Should you hold or exit MoonLake Immunotherapeutics now2025 Dividend Review & Daily Chart Pattern Signal Reports - Newser
Sector ETF performance correlation with MoonLake ImmunotherapeuticsLong Setup & Risk Controlled Daily Trade Plans - Newser
What recovery options are there for MoonLake Immunotherapeutics2025 Technical Patterns & Free Community Supported Trade Ideas - Newser
MoonLake Immunotherapeutics stock trend forecastWeekly Stock Recap & Weekly Return Optimization Alerts - Newser
Visual analytics tools that track MoonLake Immunotherapeutics performanceJuly 2025 Outlook & Short-Term High Return Ideas - Newser
Are MoonLake Immunotherapeutics' (MLTX) Rising Losses a Sign of Strategic Investment or Mounting Pressure? - simplywall.st
Real time social sentiment graph for MoonLake Immunotherapeutics [Trade Risk Assessment]Safe Entry Zone Identification - Newser
Using Python tools to backtest MoonLake Immunotherapeutics strategies [July 2025 Macro Moves]Real-Time Volume Analysis Alerts - Newser
MoonLake Immunotherapeutics: Maintaining A Small Holding (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics: Robust Financials and Promising Phase 3 VELA Program Back Strong Buy Rating - AInvest
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 VELA Program and Robust Financial Position - TipRanks
Does Rising Loss at MoonLake Immunotherapeutics (MLTX) Signal Strategic Investment or Expense Control Challenges? - simplywall.st
Rising Losses Might Change the Case for Investing in MoonLake Immunotherapeutics (MLTX) - simplywall.st
Wedbush Has Negative Forecast for MLTX Q3 Earnings - Defense World
Intraday Charts Show Spike in MoonLake Immunotherapeutics ActivitySwing Trade Entry With Volume Triggers Released - beatles.ru
Leerink Partners Maintains Buy Rating on MoonLake Immunotherapeutics with $73 Price Target - AInvest
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $66 - 富途牛牛
Goldman Sachs Boosts MoonLake Pharmaceuticals Target Price to $82, Maintains "Buy" Rating - AInvest
Clear Street Analyst Reiterates Buy Rating for MoonLake Immunotherapeutics with $108 Price Target - AInvest
MoonLake Bets Big On Its Nanobody Drug As Key Trials Approach - Finimize
MoonLake Immunotherapeutics Reports Q2 2025 Financials - TipRanks
Clear Street Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $108 - 富途牛牛
MoonLake Immunotherapeutics reports Q2 EPS (87c), consensus (76c) - TipRanks
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock - Investing.com India
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
MoonLake Immunotherapeutics reports second quarter 2025 financial results and provides a business update - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results And Provides A Business Update - TradingView
MoonLake Immunotherapeutics Q2 Loss Widens - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - Ariva
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q2 Net Loss $0.87 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
MoonLake Immunotherapeutics's Q2 net loss widens - MarketScreener
MoonLake Immunotherapeutics SEC 10-Q Report - TradingView
MoonLake Immunotherapeutics AG - Via Ritzau
How does MoonLake Immunotherapeutics compare to its industry peersDiscover stocks with explosive potential - Jammu Links News
Is it the right time to buy MoonLake Immunotherapeutics stockFree Consultation - Jammu Links News
What drives MoonLake Immunotherapeutics stock priceFree Stock Index Interpretation - Jammu Links News
How does MoonLake Immunotherapeutics generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
Is MoonLake Immunotherapeutics stock overvalued or undervaluedMaximize gains with professional stock picks - Jammu Links News
MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy Rating - TipRanks
Is MoonLake Immunotherapeutics a growth stock or a value stockTremendous wealth creation - Jammu Links News
What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Achieve remarkable returns with smart investing - Jammu Links News
What institutional investors are buying MoonLake Immunotherapeutics stockOutstanding capital returns - Jammu Links News
0.22%
3.58%
大文字化:
|
ボリューム (24 時間):